At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
HCC Warrior Met Coal LLC
Pre-Mkt 06-12 04:17:14 EDT
94.02
-1.21
-1.27%
High96.47Low92.85Vol624.91K
Open96.11D1 Closing95.23Amplitude3.80%
Mkt Cap4.94BTradable Cap4.84BTotal Shares52.57M
T/O58.88MT/O Rate1.21%Tradable Shares51.47M
P/B--ROE--EPS0.00
52wk High--52wk Low--P/E--
Dividend--Div.Yield--ROA--

Loading ...

Warrior Met Coal Is Maintained at Buy by B. Riley Securities
Dow Jones  ·  06-11 02:19
Warrior Met Coal Is Maintained at Buy by B. Riley Securities
Warrior Met Coal Inc : B. Riley Raises Target Price to $123 From $117
THOMSON REUTERS  ·  06-10 20:04
Warrior Met Coal Inc : B. Riley Raises Target Price to $123 From $117
B. Riley Raises Price Target on Warrior Met Coal to $123 From $117, Keeps Buy Rating
MT Newswires Live  ·  06-10 19:43
B. Riley Raises Price Target on Warrior Met Coal to $123 From $117, Keeps Buy Rating
Warrior Met Coal Chief Administrative Officer Kelli K. Gant sells 20,000 shares for $2.2 million
Reuters  ·  06-05
Warrior Met Coal Chief Administrative Officer Kelli K. Gant sells 20,000 shares for $2.2 million
RBC Capital Reaffirms Their Hold Rating on Warrior Met Coal (HCC)
TIPRANKS  ·  06-04
RBC Capital Reaffirms Their Hold Rating on Warrior Met Coal (HCC)
ABBISKO-B Presents Innovative Modeling Framework for ABSK-011 in HCC at PAGE Conference
Stock News  ·  06-04
ABBISKO-B Presents Innovative Modeling Framework for ABSK-011 in HCC at PAGE Conference
Chinese Coal-Mine Disruptions Could Be Major Supply Shock for Global Markets -- Market Talk
Dow Jones  ·  05-28
Chinese Coal-Mine Disruptions Could Be Major Supply Shock for Global Markets -- Market Talk
Junshi Biosciences Announces Primary Endpoints Met in Final Analysis of Phase 3 Study for Perioperative Toripalimab plus Chemotherapy for Resectable Stage II-III NSCLC
GlobeNewswire  ·  05-27
Junshi Biosciences Announces Primary Endpoints Met in Final Analysis of Phase 3 Study for Perioperative Toripalimab plus Chemotherapy for Resectable Stage II-III NSCLC
Assessing Warrior Met Coal (HCC) Valuation After Recent Share Price Softness And Blue Creek Growth Plans
Simply Wall St.  ·  05-27
Assessing Warrior Met Coal (HCC) Valuation After Recent Share Price Softness And Blue Creek Growth Plans
Junshi Biosciences Announces Approval of Toripalimab NDA for the 1st-line treatment of HER2 Expressing Urothelial Carcinoma
GlobeNewswire  ·  05-21
Junshi Biosciences Announces Approval of Toripalimab NDA for the 1st-line treatment of HER2 Expressing Urothelial Carcinoma
Scientific Publication of Can-Fite and Vetbiolix Validates Piclidenoson’s Potential in the Multi-Billion Dollar Canine Osteoarthritis Market
GlobeNewswire  ·  05-18
Scientific Publication of Can-Fite and Vetbiolix Validates Piclidenoson’s Potential in the Multi-Billion Dollar Canine Osteoarthritis Market
A Look At Warrior Met Coal (HCC) Valuation After Early Blue Creek Spend And Strong Q1 Results
Simply Wall St.  ·  05-18
A Look At Warrior Met Coal (HCC) Valuation After Early Blue Creek Spend And Strong Q1 Results
Following Positive Phase 2a Pancreatic Cancer Data, Can-Fite Advances Namodenoson into Phase 2b Combination Study with Immunotherapy
GlobeNewswire  ·  05-13
Following Positive Phase 2a Pancreatic Cancer Data, Can-Fite Advances Namodenoson into Phase 2b Combination Study with Immunotherapy
Gyre Therapeutics Announces NMPA Acceptance of New Drug Application for F351 (hydronidone) for CHB-Induced Liver Fibrosis Treatment
GlobeNewswire  ·  05-13
Gyre Therapeutics Announces NMPA Acceptance of New Drug Application for F351 (hydronidone) for CHB-Induced Liver Fibrosis Treatment
A Look At Warrior Met Coal (HCC) Valuation As Long Term Returns Outpace Recent Share Price Moves
Simply Wall St.  ·  05-09
A Look At Warrior Met Coal (HCC) Valuation As Long Term Returns Outpace Recent Share Price Moves
Is It Time To Reassess Warrior Met Coal (HCC) After Its Recent Share Price Pullback
Simply Wall St.  ·  05-06
Is It Time To Reassess Warrior Met Coal (HCC) After Its Recent Share Price Pullback
Madrigal Adds Clinical-Stage siRNA Asset Targeting PNPLA3 to its MASH Pipeline
GlobeNewswire  ·  05-05
Madrigal Adds Clinical-Stage siRNA Asset Targeting PNPLA3 to its MASH Pipeline
Warrior Met Coal Is Maintained at Buy by UBS
Dow Jones  ·  05-02
Warrior Met Coal Is Maintained at Buy by UBS
Stock Track | Warrior Met Coal Plummets 7.41% Intraday After UBS Price Target Cut
Stock Track  ·  05-01
Stock Track | Warrior Met Coal Plummets 7.41% Intraday After UBS Price Target Cut
Stock Track | Warrior Met Coal Plunges 5.31% in Pre-Market After UBS Price Target Cut
Stock Track  ·  05-01
Stock Track | Warrior Met Coal Plunges 5.31% in Pre-Market After UBS Price Target Cut

Introduction

Company Name.
Warrior Met Coal LLC
Affiliated Markets:
NYSE
Listing Date:
--
Main Business:
Warrior Met Coal, Inc. produces and exports non-thermal metallurgical coal for the steel industry. It operates two underground mines located in Alabama. The company sells its metallurgical coal to a customer base of blast furnace steel producers located primarily in Europe, South America, and Asia. It also sells natural gas, which is extracted as a byproduct from coal production. Warrior Met Coal, Inc. was incorporated in 2015 and is headquartered in Brookwood, Alabama.
Issue price:
--